Cellceutix Meets Manufacturers To Synthesize Prurisol For Clinical Trial

7/16/2012 7:21 AM ET

Cellceutix Corp. (CTIX.OB) reported that it has been conducting meetings with manufacturers to synthesize and formulate its lead psoriasis drug, Prurisol, for a Phase 2/3 clinical trial.

Cellceutix said the U.S. Food and Drug Administration recently told the company that an application for a 505(b)(2) designation for Prurisol would be an acceptable approach; allowing the Company to advance Prurisol immediately into advanced stages of clinical trials.

Click here to receive FREE breaking news email alerts for Cellceutix Corp and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 343 Articles

Editors Pick

Upbeat Economic Data Contributes To Rally On Wall Street - U.S. Commentary

Stocks moved sharply higher over the course of the trading day on Friday, more than offsetting the weakness seen on Thursday. In a reversal from the previous session, the markets benefited from some upbeat U.S. economic data as well as comments from a Federal Reserve official. The major averages saw further upside going into the close, with the Dow and the S&P 500 reaching new record highs.

PETA: IRS Targeting Neither New Nor Limited To Conservative Causes

As the IRS targeting scandal continues to make headlines, animal-protection charity People for the Ethical Treatment of Animals, or PETA, claims that conservative groups are not the only ones that have faced increased scrutiny from the agency.

Polls Shows Below Average Interest In IRS, Benghazi Stories

While the IRS targeting scandal has taken center stage on Capitol Hill on Friday, the results of a new Gallup poll showed that the American public's interest in the story is comparatively low based on historical measures. The poll showed that 54 percent of Americans are following the news that the IRS targeted conservative groups for greater scrutiny "very" or "somewhat" closely.